How to buy Lyra Therapeutics stock | $7.18

Lyra Therapeutics, Inc is a biotechnology business based in the US. Lyra Therapeutics shares (LYRA) are listed on the NASDAQ and all prices are listed in US Dollars. Lyra Therapeutics employs 43 staff and has a market cap (total outstanding shares value) of 0.00.

Lyra Therapeutics stock price (NASDAQ: LYRA)

Use our graph to track the performance of LYRA stocks over time.

Lyra Therapeutics shares at a glance

• Key figures

Information last updated 2021-07-28.

Latest market close	$7.18
52-week range	$6.18 - $15.83
50-day moving average	$8.06
200-day moving average	$10.33
Wall St. target price	$26.00
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	N/A

Buy Lyra Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy Lyra Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Lyra Therapeutics, Inc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Lyra Therapeutics price performance over time

Historical closes compared with the close of $7.18 from 2021-05-28

1 week (2021-07-25)	N/A
1 month (2021-07-02)	-12.55%
3 months (2021-05-05)	-14.93%
6 months (2021-02-01)	N/A

1 year (2020-08-01)	N/A
2 years (2019-08-01)	N/A
3 years (2018-08-01)	N/A
5 years (2016-08-01)	N/A

Lyra Therapeutics financials

Gross profit TTM	$0
Return on assets TTM	-28.36%
Return on equity TTM	-50.9%
Profit margin	0%
Book value	$5.21
Market capitalisation	$86.2 million

TTM: trailing 12 months

Shorting Lyra Therapeutics shares

There are currently 239,441 Lyra Therapeutics shares held short by investors – that's known as Lyra Therapeutics's "short interest". This figure is 0.3% up from 238,665 last month.

There are a few different ways that this level of interest in shorting Lyra Therapeutics shares can be evaluated.

Lyra Therapeutics's "short interest ratio" (SIR)

Lyra Therapeutics's "short interest ratio" (SIR) is the quantity of Lyra Therapeutics shares currently shorted divided by the average quantity of Lyra Therapeutics shares traded daily (recently around 145115.75757576). Lyra Therapeutics's SIR currently stands at 1.65. In other words for every 100,000 Lyra Therapeutics shares traded daily on the market, roughly 1650 shares are currently held short.

However Lyra Therapeutics's short interest can also be evaluated against the total number of Lyra Therapeutics shares, or, against the total number of tradable Lyra Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Lyra Therapeutics's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 Lyra Therapeutics shares in existence, roughly 20 shares are currently held short) or 0.0456% of the tradable shares (for every 100,000 tradable Lyra Therapeutics shares, roughly 46 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Lyra Therapeutics.

Find out more about how you can short Lyra Therapeutics stock.

Lyra Therapeutics share dividends

We're not expecting Lyra Therapeutics to pay a dividend over the next 12 months.

Lyra Therapeutics overview

Lyra Therapeutics, Inc. , a clinical-stage therapeutics company, focuses on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. The company's XTreo technology platform is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. Its product candidates include LYR-210, an anti-inflammatory implantable drug matrix for the treatment of chronic rhinosinusitis (CRS), which is in Phase II clinical trial; and LYR-220 for CRS patients with and without nasal polyps. The company was formerly known as 480 Biomedical, Inc. and changed its name to Lyra Therapeutics, Inc. in July 2018.

Frequently asked questions

What percentage of Lyra Therapeutics is owned by insiders or institutions?
Currently 1.412% of Lyra Therapeutics shares are held by insiders and 77.815% by institutions. How many people work for Lyra Therapeutics?
Latest data suggests 43 work at Lyra Therapeutics. When does the fiscal year end for Lyra Therapeutics?
Lyra Therapeutics's fiscal year ends in December. Where is Lyra Therapeutics based?
Lyra Therapeutics's address is: 480 Arsenal Way, Watertown, MA, United States, 02472 What is Lyra Therapeutics's ISIN number?
Lyra Therapeutics's international securities identification number is: US55234L1052 What is Lyra Therapeutics's CUSIP number?
Lyra Therapeutics's Committee on Uniform Securities Identification Procedures number is: 55234L105